Everolimus As Second-Line Treatment In Metastatic Renal Cell Carcinoma (Mrcc) After First-Line Pazopanib (The Rescue Study): A Retrospective Analysis By The Hellenic Gu Cancer Group (Hgucg) With International Collaboration

e15601 Background: Pazopanib and everolimus are approved first and second line therapies in mRCC, respectively. However, real-world data on the efficacy and safety of everolimus as second-line treatment after pazopanib are lacking. Methods: Medical charts of mRCC patients from 8 centers from Greece and Spain were reviewed. Major inclusion criterion for this retrospective analysis was: first-line therapy with pazopanib AND 2nd-line therapy with everolimus. No other first- or second-line therapies were allowed. Results: Data from 30 patients (Table 1) treated with second-line everolimus between 19 Sep 2011 and 16 Jan 2014 are reported. Median treatment duration with pazopanib and everolimus was 5.7 and 3.5 months, respectively. Median PFS from everolimus initiation was 3.5 months (95% CI 2.4-6.3) and median OS 8.9 months (95% CI 6-15.9). After a median fup of 27 months, combined OS since pazopanib initiation was 14.8 months (95% CI 10.5-22.3). Best responses on everolimus were 15% PR, 27% SD and 58% PD. Mos...